
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential...
Biopharma,oncology,late stage clinical trials,immunotherapies,and hematologic oncology
Sellas life sciences group, inc operates in the Biotechnology research industry.
Sellas life sciences group, inc's revenue is 11m - 100m
Sellas life sciences group, inc has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.